Abstract
Cervical dystonia (CD) causes involuntary muscle spasms and is often associated with pain. Recently, botulinum toxin type B (BTX-B) (Myobloc™, Elan South San Francisco, CA, USA) was approved for general use in the treatment of CD in the USA. In two large pivotal trials, BTX-B was found to be safe and effective in decreasing the movements, pain and disability associated with CD. Benefits were noted both in patients who no longer respond and in those who continue to respond to botulinum toxin type A (BTX-A). BTX-B offers an additional therapeutic option for patients with CD.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2191-2199 |
| Number of pages | 9 |
| Journal | Expert Opinion on Investigational Drugs |
| Volume | 10 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 31 2001 |
| Externally published | Yes |
Keywords
- Botulinum toxin
- Cervical dystonia
- Chemodenervation
- Myobloc™
- NeuroBloc®
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)